Tetragenetics Moves Into Drug Development

Hires Dr. Charlotte Mcdonagh As SVP Development and Translational Science

Boston, MA, April 2020 — TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced that Charlotte McDonagh has joined the executive team as Senior Vice President, Development and Translational Science. Dr. McDonagh has extensive experience in the development of antibody-based therapeutics, including bispecific antibodies and antibody drug conjugates.

“We are thrilled to have Dr. McDonagh joining the TetraGenetics team and leading our translation and drug development activities. Charlotte brings to the company deep skills gained from many years guiding the development of multiple drugs through IND filings and early clinical trials said Doug Kahn, CEO of TetraGenetics.

Dr. McDonagh previously held leadership roles at Magenta Therapeutics serving as Vice President, Head of Biotherapeutics (2017-2020), and Merrimack Pharmaceuticals, where she led discovery and early clinical stage programs (2007-2016). Prior to joining Merrimack, she was at Seattle Genetics focusing on therapeutic antibody discovery and protein engineering projects. Charlotte holds a doctorate in biochemistry from the University of Leicester, U.K, and an undergraduate degree in biochemistry from the University of Bristol, U.K.

About TetraGenetics: TetraGenetics is focused on the discovery and development of first-in-class biologic medicines for pain, autoimmune diseases, and fibrosis. The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins. TetraGenetics is actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. For more information, please visit: www.tetragenetics.com.

Contact for TetraGenetics:
Suzanne Gibbons-Neff